Balyasny Asset Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Balyasny Asset Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,189	Closed	-$5.72K	–	2889
2023 Q2	$5.72K	Buy	+19,189	New	+$5.79K	﹤0.01%	2196
2022 Q2	–	Sell	-14,715	Closed	-$142K	–	3323
2022 Q1	$142K	Sell	14,715 -385,285	-96%	-$3.45M	﹤0.01%	2087
2021 Q4	$3.97M	Hold	400,000	–	–	0.01%	919
2021 Q3	$3.96M	Hold	400,000	–	–	0.02%	903
2021 Q2	$3.92M	Hold	400,000	–	–	0.02%	798
2021 Q1	$3.88M	Buy	+400,000	New	+$3.92M	0.02%	787

Balyasny Asset Management's GRNA Position: Q3 2023 in Review

Balyasny Asset Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 19,189 shares — an estimated $5.72K sold.

Balyasny Asset Management first reported a position in GRNA in Q1 2021 and held it in 6 quarters. The position peaked at $3.97M in Q4 2021. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Balyasny Asset Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Balyasny Asset Management sold 19,189 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $5.72K.
Balyasny Asset Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2021 and held it in 6 quarters.
Balyasny Asset Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $3.97M in Q4 2021.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Balyasny Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.